A dramatic rise in type 2 diabetes has led to an increase in peripheral neuropathy. New research published in Nature from the lab of Clifford Woolf, led by Sara Hakim, at Boston Children's Hospital ...
The FDA approved the first drug in its class that targets moderate to severe acute pain in adults, without being addictive ...
The condition is thought to be caused by direct peripheral nerve cell damage which disrupts or rewires normal nerve signaling pathways, resulting in persistent pain, they add. Prompted by the ...
AlgoTherapeutix announces results of its phase 2 “ACT” trial of ATX01 in chemotherapy-induced peripheral neuropathy: Paris, France Wednesday, February 19, 2025, 13:00 Hrs [IST ...
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA).
One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...
Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.
On Wednesday, the U.S. Food and Drug Administration approved a new pain management drug which could change the way healthcare providers address pain management. Suzetrigine, also known as Journavx, is ...
(1) “Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy) (ACT)”. The purpose of this clinical trial is to compare the efficacy of twice daily ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback